Statera Biopharma, Inc. (STAB) Stock Plunged 10.06% Today, Here’s Why

Statera Biopharma, Inc. (STAB) stock plummeted 10.06% in the current market trading session at the price of $0.28 despite no fundamental updates.

STAB Filed Form 12b-25

On 31st March 2022, STAB announced filing a Form 12b-25 with U.S. SEC. The Form has filed to extend the due date till 15th April 2022 for filing its annual report on Form 10-K for fiscal 2021. The stock experienced a delay in completing its financial statements due to the absence of mandatory data to conclude the annual report. Therefore, Statera remained unable to finalize its financial results for the year that ended on 31st December 2021.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The company expects to file the annual report by 15th April 2022. Following this announcement, the stock delayed its webcast and conference call to deliver its financial results for the full year of 2021. The company will announce the new schedule for the webcast and conference call soon.

STAB Closed US$5.7M Public Offering

Previously on 24th March 2022, STAB announced the closure of its earlier reported public offering of roughly 12,555,555 units. The offering has a public price of US$0.45 per unit and was subject to customary closing conditions. The stock earned gross proceeds of US$5.7M from the public offering. The company has also granted underwriters an option to buy 1,883,333 warrants at the public offering price of UW$0.01 per warrant.

STAB Stock

Statera Biopharma is a clinical-stage and technology-based biopharmaceutical firm that employs its proprietary platform to develop unique therapies targeting anemia, neutropenia, autoimmune, cancers, and emerging viruses. The company’s proprietary technology is based on rebalancing human immunity and restoring homeostasis.

STAB owns a large portfolio of toll-like receptor that plays a critical role in rebuilding the body’s immune system. The stock is devising therapies to evoke a durable response of antibodies and killer T-cells within patients to activate immune protection against infectious diseases.

Most Popular